Taysha Gene Therapies, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2020 | $-30.7M | $-30.8M | $82.0K | $3.4M |
| FY2021 | $-117.0M | $-132.3M | $15.3M | $18.2M |
| FY2022 | $-88.4M | $-109.0M | $20.6M | $18.0M |
| FY2023 | $-73.0M | $-76.9M | $3.9M | $7.9M |
| FY2024 | $-81.2M | $-81.6M | $374.0K | $13.1M |
| FY2025 | $-93.1M | $-93.8M | $738.0K | $13.3M |